News
📈 Stocks
BlossomHill Therapeutics Falls Post-$150M IPO in Cautious Biotech Debut
(46 days ago)
BlossomHill Therapeutics' post-IPO decline highlights investor caution toward cancer drugmakers, with the $150 million debut faltering on U.S. exchanges as biotech sentiment…